Valeant Pharmaceuticals International (VRX) : Net money flow in Valeant Pharmaceuticals International (VRX) was negative ($4.16 million) and the inflow of money on uptick was $97.18 million, whereas, the outflow of money on downticks amounted to $101.35 million on Tuesday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.96. The block trades show that the large investors, were aggressive sellers in the stock. The total value of block trades on upticks was only $5.72 million. On the other hand, the total value of block trades done on downticks was $9.24 million. The ratio of uptick to downtick block trades was 0.62. The money flow in block trades was negative ($3.52). Valeant Pharmaceuticals International (VRX) gained $0.12 cent during the day and reached $30.37, a gain of 0.38% over the previous day.
Also, In a research note released to the investors, Morgan Stanley upgrades its rating on Valeant Pharmaceuticals International (NYSE:VRX).The analysts at the brokerage house have a current rating of Overweight on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. In a recent information released to the investors, Morgan Stanley raises the new price target from $33 per share to $42 per share. The rating by the firm was issued on August 17, 2016.
Valeant Pharmaceuticals International, Inc. has dropped 3.04% in the last five trading days, however, the shares have posted positive gains of 44.81% in the last 4 weeks. Valeant Pharmaceuticals International, Inc. is up 1.54% in the last 3-month period. Year-to-Date the stock performance stands at -70.24%.
Valeant Pharmaceuticals International (NYSE:VRX): The stock was completely flat for the day, closing at $30.25 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $29.96, the stock touched an intraday high of $30.64 and a low of $29.71. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $30.25. The total trading volume on Tuesday was 17,148,958.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Valeant Pharmaceuticals International, Inc., Karabelas Argeris N, had purchased 4,000 shares in a transaction dated on August 11, 2016. The transaction was executed at $24.65 per share with total amount equaling $98,600.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.